Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Rewards & Risks
ZJK Industrial (ZJK)	$2.96	$190.39M	✅ 3 ⚠️ 2 View Analysis >
WM Technology (MAPS)	$0.37	$64.02M	✅ 3 ⚠️ 5 View Analysis >
LexinFintech Holdings (LX)	$2.09	$351.67M	✅ 3 ⚠️ 2 View Analysis >
Information Services Group (III)	$3.11	$192.6M	✅ 2 ⚠️ 1 View Analysis >
Golden Growers Cooperative (GGRO.U)	$5.00	$77.45M	✅ 2 ⚠️ 5 View Analysis >
Niagen Bioscience (NAGE)	$4.17	$332.81M	✅ 3 ⚠️ 1 View Analysis >
Cricut (CRCT)	$4.30	$902.56M	✅ 2 ⚠️ 2 View Analysis >
Village Farms International (VFF)	$2.57	$293.72M	✅ 5 ⚠️ 1 View Analysis >
BAB (BABB)	$0.94	$6.83M	✅ 2 ⚠️ 3 View Analysis >
Marine Petroleum Trust (MARP.S)	$4.91	$9.82M	✅ 2 ⚠️ 4 View Analysis >

We're going to check out a few of the best picks from our screener tool.

Codexis (CDXS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Codexis, Inc. leverages its proprietary CodeEvolver technology platform to develop and commercialize novel enzymes for therapeutics manufacturing across various global markets, with a market cap of approximately $259.06 million.

Operations: The company generates revenue primarily from its Biotechnology segment, which reported $78.09 million.

Market Cap: $259.06M

Codexis, Inc. leverages its CodeEvolver technology to drive revenue growth, recently reporting US$15.25 million for Q1 2026, a significant increase from the previous year. Despite this progress, the company remains unprofitable and faces challenges such as high volatility and an inexperienced board with an average tenure of 2.3 years. While Codexis has more cash than total debt and a sufficient cash runway for over a year, its negative return on equity indicates ongoing financial hurdles. The recent agreement to produce siRNA material highlights potential future opportunities in scaling up manufacturing capabilities within the biotechnology sector.

OPKO Health (OPK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: OPKO Health, Inc. is a healthcare company operating in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally with a market cap of approximately $860.81 million.

Operations: The company's revenue is primarily derived from two segments: Diagnostics, which generated $339.62 million, and Pharmaceutical, contributing $241.51 million.

Market Cap: $860.81M

OPKO Health, Inc. faces challenges with its unprofitability and negative return on equity of -17.68%, but it maintains a stable weekly volatility of 5% and has not diluted shareholders significantly in the past year. The company reported first-quarter revenue of US$124.2 million, down from US$149.95 million a year ago, with a net loss improvement to US$54.85 million from US$67.61 million previously. Despite increased debt levels over five years, OPKO’s short-term assets exceed both short- and long-term liabilities, providing a satisfactory financial cushion alongside an experienced board averaging 17 years in tenure.

Hyliion Holdings (HYLN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Hyliion Holdings Corp. designs and develops power generators for stationary and mobile applications, with a market cap of approximately $438.66 million.

Operations: Hyliion Holdings generates revenue from its Auto Parts & Accessories segment, totaling $3.48 million.

Market Cap: $438.66M

Hyliion Holdings Corp. is navigating the penny stock landscape with a market cap of approximately US$438.66 million and limited revenue of US$3.48 million from its Auto Parts & Accessories segment, indicating it may be pre-revenue in meaningful terms. Despite being unprofitable with a negative return on equity of -29.78%, Hyliion is debt-free and has short-term assets exceeding both its short- and long-term liabilities, providing some financial stability. Recent advancements in their KARNO reactor technology demonstrate significant potential for fuel flexibility across various applications, positioning the company to potentially capitalize on future market opportunities despite current financial challenges.

Turning Ideas Into Actions

• Click through to start exploring the rest of the 340 US Penny Stocks now.
• Want To Explore Some Alternatives? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.